2007
2007 Press Releases
Exactech to Acquire Altiva Corporation
Gainesville, Fla. -- December 10, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a rapidly growing orthopaedic device manufacturer, announced today that it intends to exercise its 2003 investment agreement option to acquire the stock and assets of Altiva Corporation, a North Carolina-based spinal products company engaged in the research, development, manufacture and marketing of spinal implant devices and related products. Altiva offers a spinal fusion product line with implants and instrumentation that address the major indicated spinal pathologies and focus areas of traditional spinal surgery.
David Petty Named President of Exactech; Joins Board of Directors
GAINESVILLE, Fla. -- December 5, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a rapidly growing orthopaedic device manufacturer, announced today that Executive Vice President David W. Petty has been promoted to president. He was also named to the board of directors.
Exactech Q3 Revenue Up 23% to $30.0M; Net Income Up 35% to $2.5M or $0.21 EPS
GAINESVILLE, Fla. -- October 29, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including hip and knee orthopaedic implants and biologic materials, announced today that revenue for the third quarter of 2007 increased 23% to $30.0 million from $24.3 million in the third quarter of 2006. Net income for the third quarter was up 35% to $2.5 million or $0.21 diluted earnings per share compared with net income of $1.8 million or $0.16 diluted earnings per share in the same quarter a year ago.
Exactech Receives Subpoena from Department of Justice
GAINESVILLE, Fla. -- December 12, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a rapidly growing orthopaedic device manufacturer, announced today that it has received a subpoena from the U.S. Department of Justice through the U.S. Attorney for the District of New Jersey requesting documents from 1998 through the present related to consulting and professional service agreements between Exactech and orthopaedic surgeons and other medical professionals.
Exactech, Inc. Named a 2007 Top Small Workplace by The Wall Street Journal
GAINESVILLE, Fla. -- October 1, 2007 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that it was named a 2007 Top Small Workplace by The Wall Street Journal and Winning Workplaces.
Exactech Q2 Revenue Up 19% to $31.6M YTD Sales Up 18% to $61.2M
GAINESVILLE, Fla. -- July 31, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that revenue for the second quarter of 2007 increased 19% to $31.6 million from $26.6 million in the second quarter of 2006. Diluted earnings per share for the quarter was $0.12 based on net income of $1.4 million. This compares with net income of $2.1 million or $0.18 diluted EPS a year ago.
Exactech Announces FDA Approval for Novation Ceramic Articulation Hip System, Adjusts 2007 Financial Targets
GAINESVILLE, Fla. – July 12, 2007 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Novation™ Ceramic AHS™ (articulation hip system) thereby granting Exactech permission to market the system.
Bob Purcell Named Exactech Vice President U.S. Sales
GAINESVILLE, Fla. – June 12, 2007 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today the appointment of Bob Purcell as vice president of U.S. sales. Purcell comes to Exactech from Smith & Nephew where he was the vice president of corporate accounts.
Exactech, Inc. Names James G. Binch to Board of Directors
GAINESVILLE, Fla. -- May 24, 2007 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced the appointment of James G. Binch to its board of directors. Binch was elected to the board of directors during the annual shareholders meeting that took place on May 16 at Exactech’s corporate headquarters in Gainesville, Fla.
Exactech Q1 Revenue Up 16% to $29.6M; Net Income Up 19% to $1.9M or $0.16 EPS
GAINESVILLE, Fla. -- April 30, 2007 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products, including orthopaedic implants and biologic materials, announced today that revenue for the first quarter of 2007 increased 16% to $29.6 million, from $25.4 million in the first quarter of 2006. Net income for the quarter was $1.9 million, or $0.16 per diluted share, a gain of 19% from the $1.6 million, or $0.14 per diluted share, in the first quarter of 2006.
Exactech, Inc. Cleared by FDA for U.S. Distribution of Equinoxe® Reverse Shoulder
GAINESVILLE, Fla. -- March 12, 2007 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Equinoxe® Reverse Shoulder, the latest component in the company’s shoulder arthroplasty line.
Exactech 2006 Revenue Up 13% to $102.4M;Net Income $7.8M or $0.67 EPS
Gainesville, Fla., February 26, 2007 -- Exactech, Inc. (Nasdaq: EXAC) announced today that revenue for fiscal year 2006 increased 13% to $102.4 million from $91.0 million in 2005. Net income for the year was $7.8 million or $0.67 diluted earnings per share for the year, compared with net income of $6.6 million or $0.57 diluted earnings per share during 2005.
Exactech Achieves 2006 Sales of Over $100 Million
Gainesville, FL, January 5, 2007 -- Exactech, Inc. (Nasdaq: EXAC), a producer and distributor of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that revenue in 2006 is anticipated to be approximately $102 million. This was the first time that the company’s annual revenue exceeded $100 million.
